{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MN",
    "query": {
      "condition": "MN"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MN&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:31:35.516Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00000775",
      "title": "A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Rochester, New York",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000775"
    },
    {
      "nct_id": "NCT06983028",
      "title": "Atacicept in Multiple Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "pMN",
        "IgAN",
        "Nephrotic Syndrome",
        "MCD",
        "FSGS"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-07-07",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983028"
    },
    {
      "nct_id": "NCT00805753",
      "title": "Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "ACTH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-01",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-10-13",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805753"
    },
    {
      "nct_id": "NCT00000813",
      "title": "A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV gp160MN (vCP125)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALVAC-RG Rabies Glycoprotein (vCP65)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": null,
      "completion_date": "1995-06",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000813"
    },
    {
      "nct_id": "NCT00000866",
      "title": "A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MN rgp120/HIV-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TBC-3B Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": null,
      "completion_date": "1999-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000866"
    },
    {
      "nct_id": "NCT00000853",
      "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 37,
      "start_date": null,
      "completion_date": "1999-01",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Rochester, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000853"
    },
    {
      "nct_id": "NCT00000868",
      "title": "A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 27,
      "start_date": null,
      "completion_date": "2000-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000868"
    },
    {
      "nct_id": "NCT07472491",
      "title": "A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Known or Highly Suspected Central Nervous System (CNS) Lesion",
        "Known or Highly Suspected Body (Excluding CNS) Lesion"
      ],
      "interventions": [
        {
          "name": "Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL",
          "type": "DRUG"
        },
        {
          "name": "MRI Scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Gadobutrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 640,
      "start_date": "2026-04-01",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07472491"
    },
    {
      "nct_id": "NCT07037927",
      "title": "Minnesota RETAIN Phase 3",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Injuries Related Work",
        "Illness Related Work",
        "Disability"
      ],
      "interventions": [
        {
          "name": "RETAIN Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2025-07-07",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07037927"
    },
    {
      "nct_id": "NCT00001096",
      "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-05-22T05:31:35.516Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001096"
    }
  ]
}